Somewhat Positive Press Coverage Somewhat Unlikely to Impact Cytokinetics (CYTK) Stock Price

Media coverage about Cytokinetics (NASDAQ:CYTK) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytokinetics earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5451124308842 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s rankings:

Shares of Cytokinetics (CYTK) traded up $0.30 during mid-day trading on Friday, reaching $8.10. The company had a trading volume of 543,100 shares, compared to its average volume of 594,823. Cytokinetics has a 12 month low of $7.00 and a 12 month high of $17.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. The company had revenue of $6.18 million during the quarter, compared to analysts’ expectations of $5.35 million. equities analysts anticipate that Cytokinetics will post -2.4 earnings per share for the current fiscal year.

A number of research firms have weighed in on CYTK. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 target price on shares of Cytokinetics in a report on Tuesday, September 26th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Cytokinetics in a research report on Sunday, September 17th. ValuEngine downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. JMP Securities reissued an “outperform” rating and set a $13.00 price target (down from $17.00) on shares of Cytokinetics in a research note on Tuesday, November 21st. They noted that the move was a valuation call. Finally, HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Cytokinetics in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $17.64.

In related news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $14.59, for a total transaction of $72,950.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $15.49, for a total value of $204,173.69. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,762 shares of company stock valued at $497,826. Company insiders own 7.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply